KR102450583B1 - 보론산 유도체 - Google Patents

보론산 유도체 Download PDF

Info

Publication number
KR102450583B1
KR102450583B1 KR1020177011643A KR20177011643A KR102450583B1 KR 102450583 B1 KR102450583 B1 KR 102450583B1 KR 1020177011643 A KR1020177011643 A KR 1020177011643A KR 20177011643 A KR20177011643 A KR 20177011643A KR 102450583 B1 KR102450583 B1 KR 102450583B1
Authority
KR
South Korea
Prior art keywords
ethyl
amino
boronic acid
acetyl
benzofuran
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177011643A
Other languages
English (en)
Korean (ko)
Other versions
KR20170062517A (ko
Inventor
마르쿠스 클라인
올리버 샤트
필립 하젤마이어
미하엘 부쉬
Original Assignee
메르크 파텐트 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메르크 파텐트 게엠베하 filed Critical 메르크 파텐트 게엠베하
Publication of KR20170062517A publication Critical patent/KR20170062517A/ko
Application granted granted Critical
Publication of KR102450583B1 publication Critical patent/KR102450583B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/025Boronic and borinic acid compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/69Boron compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020177011643A 2014-10-01 2015-10-01 보론산 유도체 Active KR102450583B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14003392 2014-10-01
EP14003392.9 2014-10-01
PCT/EP2015/002008 WO2016050359A1 (en) 2014-10-01 2015-10-01 Boronic acid derivatives

Publications (2)

Publication Number Publication Date
KR20170062517A KR20170062517A (ko) 2017-06-07
KR102450583B1 true KR102450583B1 (ko) 2022-10-04

Family

ID=51690789

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177011643A Active KR102450583B1 (ko) 2014-10-01 2015-10-01 보론산 유도체

Country Status (14)

Country Link
US (1) US10294246B2 (cg-RX-API-DMAC7.html)
EP (1) EP3201207B1 (cg-RX-API-DMAC7.html)
JP (1) JP6835711B2 (cg-RX-API-DMAC7.html)
KR (1) KR102450583B1 (cg-RX-API-DMAC7.html)
CN (1) CN107001390B (cg-RX-API-DMAC7.html)
AU (1) AU2015327346B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017006420A2 (cg-RX-API-DMAC7.html)
CA (1) CA2963205A1 (cg-RX-API-DMAC7.html)
ES (1) ES2873000T3 (cg-RX-API-DMAC7.html)
IL (1) IL251301B (cg-RX-API-DMAC7.html)
MX (1) MX370336B (cg-RX-API-DMAC7.html)
RU (1) RU2017115188A (cg-RX-API-DMAC7.html)
SG (1) SG11201702623TA (cg-RX-API-DMAC7.html)
WO (1) WO2016050359A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2717558C2 (ru) 2014-10-01 2020-03-24 Мерк Патент Гмбх Производные бороновой кислоты
KR20170062518A (ko) 2014-10-01 2017-06-07 메르크 파텐트 게엠베하 보론산 유도체
RU2017115193A (ru) 2014-10-01 2018-11-06 Мерк Патент Гмбх Производные бороновой кислоты
DK3672977T3 (da) 2017-08-24 2022-09-26 Merck Patent Gmbh Boronsyrederivater
BR112021001359A2 (pt) * 2018-07-26 2021-04-20 Merck Patent Gmbh derivados de ácido borônico
CN113135944A (zh) * 2020-01-19 2021-07-20 首药控股(北京)有限公司 硼酸衍生物
CN113135943A (zh) * 2020-01-19 2021-07-20 首药控股(北京)有限公司 硼酸衍生物
US20250340577A1 (en) * 2021-03-02 2025-11-06 Case Western Reserve University Beta-lactomase inhibitors and uses thereof
CA3217594A1 (en) * 2021-05-19 2022-11-24 William Guy Whittingham Weed control method
JP2024529468A (ja) 2021-07-29 2024-08-06 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規の[(1r)-2-(1-ベンゾフラン-3-イル)-1-{[(1s,2r,4r)-7-オキサビシクロ[2.2.1]ヘプタン-2-イル]ホルムアミド}エチル]ボロン酸の結晶性形態、その付加物、および得るためのプロセス
JP7734276B2 (ja) * 2021-10-14 2025-09-04 ショウヤオ ホールディングス(ベイジン) カンパニー, リミテッド ボロン酸誘導体
WO2023232830A1 (en) 2022-06-02 2023-12-07 Merck Patent Gmbh Boronic acid adducts

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001002424A2 (en) 1999-07-07 2001-01-11 Du Pont Pharmaceuticals Company Peptide boronic acid inhibitors of hepatitis c virus protease
US7271186B1 (en) 2002-12-09 2007-09-18 Northwestern University Nanomolar β-lactamase inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111175A0 (en) * 1993-10-07 1994-12-29 Du Pont Merck Pharma Electrophilic peptide analogs as inhibitors of trypsin-like serine proteases and pharmaceutical compositions containing them
MX2010005252A (es) * 2007-11-13 2011-04-11 Novartis Int Pharm Ltd Inhibidores de beta-lactamasa.
AR075090A1 (es) * 2008-09-29 2011-03-09 Millennium Pharm Inc Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
JP6129203B2 (ja) * 2011-12-22 2017-05-17 アレス トレーディング ソシエテ アノニム α−アミノボロン酸誘導体、選択性免疫プロテアソーム阻害剤
RU2717558C2 (ru) 2014-10-01 2020-03-24 Мерк Патент Гмбх Производные бороновой кислоты
KR20170062518A (ko) 2014-10-01 2017-06-07 메르크 파텐트 게엠베하 보론산 유도체
RU2017115193A (ru) 2014-10-01 2018-11-06 Мерк Патент Гмбх Производные бороновой кислоты

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001002424A2 (en) 1999-07-07 2001-01-11 Du Pont Pharmaceuticals Company Peptide boronic acid inhibitors of hepatitis c virus protease
US7271186B1 (en) 2002-12-09 2007-09-18 Northwestern University Nanomolar β-lactamase inhibitors

Also Published As

Publication number Publication date
MX2017004046A (es) 2017-06-19
KR20170062517A (ko) 2017-06-07
RU2017115188A3 (cg-RX-API-DMAC7.html) 2019-03-29
IL251301B (en) 2022-02-01
CN107001390A (zh) 2017-08-01
AU2015327346B2 (en) 2019-12-05
JP2017536335A (ja) 2017-12-07
MX370336B (es) 2019-12-10
US10294246B2 (en) 2019-05-21
IL251301A0 (en) 2017-05-29
CN107001390B (zh) 2020-11-27
RU2017115188A (ru) 2018-11-06
SG11201702623TA (en) 2017-04-27
EP3201207A1 (en) 2017-08-09
EP3201207B1 (en) 2021-02-24
AU2015327346A1 (en) 2017-05-18
US20180105539A1 (en) 2018-04-19
ES2873000T3 (es) 2021-11-03
JP6835711B2 (ja) 2021-02-24
BR112017006420A2 (pt) 2017-12-19
WO2016050359A1 (en) 2016-04-07
CA2963205A1 (en) 2016-04-07

Similar Documents

Publication Publication Date Title
KR102450583B1 (ko) 보론산 유도체
KR102457840B1 (ko) 보론산 유도체
US10640520B2 (en) Boronic acid derivatives
US10253049B2 (en) Boronic acid derivatives

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20170427

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200925

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220125

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20220629

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20220929

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20220929

End annual number: 3

Start annual number: 1

PG1601 Publication of registration